Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
37.00
+0.89 (2.46%)
At close: Jun 10, 2026, 4:00 PM EDT
38.29
+1.29 (3.49%)
After-hours: Jun 10, 2026, 5:22 PM EDT
Enliven Therapeutics Employees
Enliven Therapeutics had 61 employees as of March 31, 2026. The number of employees decreased by 4 or -6.15% compared to the same quarter last year.
Employees
61
Change
-4
Growth
-6.15%
Revenue / Employee
n/a
Profits / Employee
-$1,619,295
Market Cap
2.25B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 61 | -4 | -6.15% |
| Dec 31, 2025 | 60 | -2 | -3.23% |
| Sep 30, 2025 | 65 | 8 | 14.04% |
| Jun 30, 2025 | 63 | 11 | 21.15% |
| Mar 31, 2025 | 65 | 15 | 30.00% |
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Sep 30, 2024 | 57 | 13 | 29.55% |
| Jun 30, 2024 | 52 | 15 | 40.54% |
| Mar 31, 2024 | 50 | 21 | 72.41% |
| Dec 31, 2023 | 46 | 17 | 58.62% |
| Sep 30, 2023 | 44 | 20 | 83.33% |
| Jun 30, 2023 | 37 | 13 | 54.17% |
| Mar 31, 2023 | 29 | - | - |
| Sep 30, 2022 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| ADMA Biologics | 647 |
| Intellia Therapeutics | 377 |
| Harmony Biosciences Holdings | 293 |
| Immunome | 206 |
| Celldex Therapeutics | 198 |
| Pharvaris | 134 |
| Aurinia Pharmaceuticals | 128 |
ELVN News
- 2 days ago - Enliven initiated with a Buy at Stifel - TheFly
- 6 days ago - Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 days ago - Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress - PRNewsWire
- 8 days ago - Enliven price target raised to $62 from $45 at Mizuho - TheFly
- 14 days ago - Enliven Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 20 days ago - Enliven Therapeutics to Present at Upcoming Investor Conferences - PRNewsWire
- 4 weeks ago - Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress - TheFly
- 4 weeks ago - Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML - PRNewsWire